Trials / Unknown
UnknownNCT04291053
The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19
The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 550 (estimated)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were infected and over 2000 people died all over the world.There is no specific drug treatment for this disease. This study is planned to observe the efficacy and safety of Huaier granule in the adjuvant treatment COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Huaier Granule | standard treatment + Huaier Granule 20g po tid for 2weeks |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2020-08-01
- Completion
- 2020-09-01
- First posted
- 2020-03-02
- Last updated
- 2020-03-17
Source: ClinicalTrials.gov record NCT04291053. Inclusion in this directory is not an endorsement.